Insulin- and quercetin-loaded liquid crystalline nanoparticles: implications on oral bioavailability, antidiabetic and antioxidant efficacy

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Dandona P, Thusu K, Cook S et al. Oxidative damage to DNA in diabetes mellitus. Lancet 347(8999), 444–445 (1996).
  Medline CASGoogle Scholar
• 2 Houstis N, Rosen ED, Lander ES. Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature 440(7086), 944–948 (2006).
  Medline CASGoogle Scholar
• 3 Sharma S, Chopra K, Kulkarni SK. Effect of insulin and its combination with resveratrol or curcumin in attenuation of diabetic neuropathic pain: participation of nitric oxide and TNF-alpha. Phytother. Res. 21(3), 278–283 (2007).
  Medline CASGoogle Scholar
• 4 Coskun O, Kanter M, Korkmaz A, Oter S. Quercetin, a flavonoid antioxidant, prevents and protects streptozotocin-induced oxidative stress and β-cell damage in rat pancreas. Pharmacol. Res. 51(2), 117–123 (2005).
  Medline CASGoogle Scholar
• 5 Shukla R, Barve V, Padhye S, Bhonde R. Reduction of oxidative stress-induced vanadium toxicity by complexing with a flavonoid, quercetin: a pragmatic therapeutic approach for diabetes. Biometals 19(6), 685–693 (2006).
  Medline CASGoogle Scholar
• 6 Chitkara D, Nikalaje SK, Mittal A, Chand M, Kumar N. Development of quercetin nanoformulation and in vivo evaluation using streptozotocin induced diabetic rat model. Drug Deliv. Transl. Re. 2(2), 112–123 (2012). •• Demonstrated relevance of quercetin in streptozotocin-induced diabetic rat model.
  Medline CASGoogle Scholar
• 7 Hodgson J, Watts G, Playford DA, Burke V, Croft K. Coenzyme Q10 improves blood pressure and glycaemic control: a controlled trial in subjects with Type 2 diabetes. Eur. J. Clin. Nutr. 56(11), 1137–1142 (2002).
  Medline CASGoogle Scholar
• 8 Agrawal AK, Harde H, Thanki K, Jain S. Improved stability and antidiabetic potential of insulin-containing folic acid functionalized polymer stabilized multilayered liposomes following oral administration. Biomacromolecules 15(1), 350–360 (2014). •• Important publication correlated to current work of oral delivery of insulin.
  Medline CASGoogle Scholar
• 9 Agrawal AK, Urimi D, Harde H, Kushwah V, Jain S. Folate appended chitosan nanoparticles augment the stability, bioavailability and efficacy of insulin in diabetic rats following oral administration. RSC Adv. 5(127), 105179–105193 (2015). •• Important publication correlated to current work of oral delivery of insulin.
  CASGoogle Scholar
• 10 Agrawal AK, Gupta PN, Khanna A et al. Development and characterization of in situ gel system for nasal insulin delivery. Pharmazie 65(3), 188–193 (2010).
  Medline CASGoogle Scholar
• 11 Rai VK, Mishra N, Agrawal AK, Jain S, Yadav NP. Novel drug delivery system: an immense hope for diabetics. Drug Deliv. 23(7), 2371–2390 (2016).
  Medline CASGoogle Scholar
• 12 Owens DR, Zinman B, Bolli G. Alternative routes of insulin delivery. Diabet. Med. 20(11), 886–898 (2003).
  Medline CASGoogle Scholar
• 13 Dentin R, Girard J, Postic C. Carbohydrate responsive element binding protein (ChREBP) and sterol regulatory element binding protein-1c (SREBP-1c): two key regulators of glucose metabolism and lipid synthesis in liver. Biochimie 87(1), 81–86 (2005).
  Medline CASGoogle Scholar
• 14 Goldberg M, Gomez-Orellana I. Challenges for the oral delivery of macromolecules. Nat. Rev. Drug Discov. 2(4), 289–295 (2003).
  Medline CASGoogle Scholar
• 15 Graefe EU, Wittig J, Mueller S et al. Pharmacokinetics and bioavailability of quercetin glycosides in humans. J. Clin. Pharmacol. 41(5), 492–499 (2001).
  Medline CASGoogle Scholar
• 16 Jain AK, Thanki K, Jain S. Co-encapsulation of tamoxifen and quercetin in polymeric nanoparticles: implications on oral bioavailability, antitumor efficacy and drug-induced toxicity. Mol. Pharm. 10(9), 3459–3474 (2013). •• Coencapsulation of drugs in a single carrier system for improved oral bioavailability.
  Medline CASGoogle Scholar
• 17 Swarnakar NK, Thanki K, Jain S. Lyotropic liquid crystalline nanoparticles of CoQ10: implication of lipase digestibility on oral bioavailability, in vivo antioxidant activity and in vitro–in vivo relationships. Mol. Pharm. 11(5), 1435–1449 (2014).
  Medline CASGoogle Scholar
• 18 Wadsäter M, Barauskas J, Nylander T, Tiberg F. Formation of highly structured cubic micellar lipid nanoparticles of soy phosphatidylcholine and glycerol dioleate and their degradation by triacylglycerol lipase. ACS Appl. Mater. Interfaces 6(10), 7063–7069 (2014).
  MedlineGoogle Scholar
• 19 Agrawal AK, Kumar K, Swarnakar NK, Kushwah V, Jain S. ‘Liquid crystalline nanoparticles’: rationally designed vehicle to improve stability and therapeutic efficacy of insulin following oral administration. Mol. Pharm. 14(6), 1874–1882 (2017). •• Development of liquid crystalline nanoparticles (LCNPs) for improved oral delivery of insulin.
  Medline CASGoogle Scholar
• 20 Kraineva J, Smirnovas V, Winter R. Effects of lipid confinement on insulin stability and amyloid formation. Langmuir 23(13), 7118–7126 (2007).
  Medline CASGoogle Scholar
• 21 Agrawal AK, Harde H, Thanki K, Jain S. Improved stability and antidiabetic potential of insulin containing folic acid functionalized polymer stabilized multilayered liposomes following oral administration. Biomacromolecules 15(1), 350–360 (2013).
  MedlineGoogle Scholar
• 22 Jain S, Patil SR, Swarnakar NK, Agrawal AK. Oral delivery of doxorubicin using novel polyelectrolyte-stabilized liposomes (layersomes). Mol. Pharm. 9(9), 2626–2635 (2012).
  Medline CASGoogle Scholar
• 23 Tripathi S, Kushwah V, Thanki K, Jain S. Triple antioxidant SNEDDS formulation with enhanced oral bioavailability: implication of chemoprevention of breast cancer. Nanomedicine 12(6), 1431–1443 (2016).
  Medline CASGoogle Scholar
• 24 Jain S, Jain AK, Pohekar M, Thanki K. Novel self-emulsifying formulation of quercetin for improved in vivo antioxidant potential: implications for drug-induced cardiotoxicity and nephrotoxicity. Free Radic. Biol. Med. 65, 117–130 (2013).
  Medline CASGoogle Scholar
• 25 Jain S, Patil SR, Swarnakar NK, Agrawal AK. Oral delivery of doxorubicin using novel polyelectrolyte-stabilized liposomes (layersomes). Mol. Pharm. 9(9), 2626–2635 (2012).
  Medline CASGoogle Scholar
• 26 Johnsson M, Lam Y, Barauskas J, Tiberg F. Aqueous phase behavior and dispersed nanoparticles of diglycerol monooleate/glycerol dioleate mixtures. Langmuir 21(11), 5159–5165 (2005).
  Medline CASGoogle Scholar
• 27 Swarnakar NK, Thanki K, Jain S. Bicontinuous cubic liquid crystalline nanoparticles for oral delivery of doxorubicin: implications on bioavailability, therapeutic efficacy and cardiotoxicity. Pharm. Res. 31(5), 1219–1238 (2014). •• Extensive characterization of LCNPs for oral delivery of doxorubicin.
  Medline CASGoogle Scholar
• 28 Jain S, Bhankur N, Swarnakar NK, Thanki K. Phytantriol-based ‘stealth’ lyotropic liquid crystalline nanoparticles for improved antitumor efficacy and reduced toxicity of docetaxel. Pharm. Res. 32(10), 3282–3292 (2015).
  Medline CASGoogle Scholar
• 29 Christiansen A, Backensfeld T, Weitschies W. Effects of nonionic surfactants on in vitro triglyceride digestion and their susceptibility to digestion by pancreatic enzymes. Eur. J. Pharm. Sci. 41(2), 376–382 (2010).
  Medline CASGoogle Scholar
• 30 Higuchi T. Mechanism of sustained-action medication. Theoretical analysis of rate of release of solid drugs dispersed in solid matrices. J. Pharm. Sci. 52(12), 1145–1149 (1963).
  Medline CASGoogle Scholar
• 31 Fong WK, Hanley TL, Thierry B, Kirby N, Boyd BJ. Plasmonic nanorods provide reversible control over nanostructure of self-assembled drug delivery materials. Langmuir 26(9), 6136–6139 (2010).
  Medline CASGoogle Scholar
• 32 Hilgers AR, Conradi RA, Burton PS. Caco-2 cell monolayers as a model for drug transport across the intestinal mucosa. Pharm. Res. 7(9), 902–910 (1990).
  Medline CASGoogle Scholar
• 33 Asada H, Douen T, Waki M et al. Absorption characteristics of chemically modified-insulin derivatives with various fatty acids in the small and large intestine. J. Pharm. Sci. 84(6), 682–687 (1995).
  Medline CASGoogle Scholar
• 34 Wang L, Sun Y, Shi C et al. Uptake, transport and peroral absorption of fatty glyceride grafted chitosan copolymer–enoxaparin nanocomplexes: influence of glyceride chain length. Acta Biomater. 10(8), 3675–3685 (2014).
  Medline CASGoogle Scholar
• 35 Zeng N, Gao X, Hu Q et al. Lipid-based liquid crystalline nanoparticles as oral drug delivery vehicles for poorly water-soluble drugs: cellular interaction and in vivo absorption. Int. J. Nanomedicine 7, 3703–3718 (2012). • Publication demonstrating the potential of LCNPs in oral delivery of hydrophobic drugs.
  Medline CASGoogle Scholar
• 36 Bummer PM. Physical chemical considerations of lipid-based oral drug delivery-solid lipid nanoparticles. Crit. Rev. Ther. Drug Carrier Syst. 21(1), 1–20 (2004).
  Medline CASGoogle Scholar
• 37 Kannappan S, Anuradha CV. Insulin sensitizing actions of fenugreek seed polyphenols, quercetin and metformin in a rat model. Indian J. Med. Res. 129(4), 401–408 (2009).
  Medline CASGoogle Scholar
• 38 Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 414(6865), 813–820 (2001).
  Medline CASGoogle Scholar
• 39 Suh SW, Shin BS, Ma H et al. Glucose and NADPH oxidase drive neuronal superoxide formation in stroke. Ann. Neurol. 64(6), 654–663 (2008).
  Medline CASGoogle Scholar
• 40 Annapurna A, Reddy CS, Akondi RB, Rao SR. Cardioprotective actions of two bioflavonoids, quercetin and rutin, in experimental myocardial infarction in both normal and streptozotocin-induced Type 1 diabetic rats. J. Pharm. Pharmacol. 61(10), 1365–1374 (2009).
  Medline CASGoogle Scholar
• 41 Sánchez M, Galisteo M, Vera R et al. Quercetin downregulates NADPH oxidase, increases eNOS activity and prevents endothelial dysfunction in spontaneously hypertensive rats. J. Hypertens. 24(1), 75–84 (2006). •• Demonstrated regulation of NADPH levels via quercetin.
  Medline CASGoogle Scholar